Skip to main content
Erschienen in:

03.02.2022 | Systematic Review/Meta-analysis

Systematic review of atypical hemolytic uremic syndrome biomarkers

verfasst von: Rupesh Raina, Sidharth K. Sethi, Marie-Agnès Dragon-Durey, Amrit Khooblall, Divya Sharma, Priyanka Khandelwal, Ron Shapiro, Olivia Boyer, Hui Kim Yap, Arvind Bagga, Christoph Licht

Erschienen in: Pediatric Nephrology | Ausgabe 7/2022

Einloggen, um Zugang zu erhalten

Abstract

Background and objectives

Observing biomarkers that affect alternative pathway dysregulation components may be effective in obtaining a new and more rapid diagnostic portrayal of atypical hemolytic uremic syndrome. We have conducted a systematic review on the aHUS biomarkers: C3, C5a, C5b-9, factor B, complement factor B, H, and I, CH50, AH50, d-dimer, as well as anti-CFH antibodies.

Methods

An exhaustive literature search was conducted for aHUS patient population plasma/serum, collected/reported at the onset of diagnosis. A total of 60 studies were included with the data on 837 aHUS subjects, with at least one biomarker reported.

Results

The biomarkers C3 [mean (SD): 72.1 (35.0), median: 70.5 vs. reference range: 75–175 mg/dl, n = 752]; CH50 [28.3 (32.1), 24.3 vs. 30–75 U/ml, n = 63]; AH50 [27.6% (30.2%), 10% vs. ≥ 46%, n = 23]; and CFB [13.1 (6.6), 12.4, vs. 15.2–42.3 mg/dl, n = 19] were lower among aHUS subjects as compared with the reference range.
The biomarkers including C4 [mean (SD): 20.4 (9.5), median: 20.5 vs. reference range: 14–40 mg/dl, n = 343]; C4d [7.2 (6.5), 4.8 vs. ≤ 9.8 μg/ml, n = 108]; CFH [40.2 (132.3), 24.5 vs. 23.6–43.1 mg/dl, n = 123 subjects]; and CFI [8.05 (5.01), 6.55 mg/dl vs. 4.4–18.1 mg/dl, n = 38] were all observed to be within the reference range among aHUS subjects.
The biomarkers C5a [mean (SD): 54.9 (32.9), median: 48.8 vs. reference range: 10.6–26.3 mg/dl, n = 117]; C5b-9 [466.0 (401.4), 317 (186–569.7) vs. ≤ 250 ng/ml, n = 174]; Bb [2.6 (2.1), 1.9 vs. ≤ 1.6 μg/ml, n = 77] and d-dimer [246 (65.05), 246 vs. < 2.2 ng/ml, 2, n = 2 subjects] were higher among patients with aHUS compared with the reference range.

Conclusion

If a comprehensive complement profile were built using our data, aHUS would be identified by low levels of C3, CH50, AH50, and CFB along with increased levels of C5a, C5b-9, Bb, anti-CFH autoantibodies, and d-dimer.

Graphical abstract

A higher resolution version of the Graphical abstract is available as Supplementary information.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
7.
Zurück zum Zitat Nguyen MH, Mathew JJ, Denunzio TM, Carmichael MG (2014) Diagnosis of atypical hemolytic uremic syndrome and response to eculizumab therapy. Hawaii J Med Public Health 73(9 Suppl 1):22–24PubMedPubMedCentral Nguyen MH, Mathew JJ, Denunzio TM, Carmichael MG (2014) Diagnosis of atypical hemolytic uremic syndrome and response to eculizumab therapy. Hawaii J Med Public Health 73(9 Suppl 1):22–24PubMedPubMedCentral
14.
Zurück zum Zitat Esparza-Gordillo J, Goicoechea de Jorge E, Buil A, Carreras Berges L et al (2005) Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32 [published correction appears in Hum Mol Genet 14:1107]. Hum Mol Genet 14:703–712. https://doi.org/10.1093/hmg/ddi066CrossRefPubMed Esparza-Gordillo J, Goicoechea de Jorge E, Buil A, Carreras Berges L et al (2005) Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32 [published correction appears in Hum Mol Genet 14:1107]. Hum Mol Genet 14:703–712. https://​doi.​org/​10.​1093/​hmg/​ddi066CrossRefPubMed
39.
Zurück zum Zitat Al Ustwani O, Lohr J, Dy G, LeVea C et al (2014) Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review. J Gastrointest Oncol 5:E30–E33PubMedPubMedCentral Al Ustwani O, Lohr J, Dy G, LeVea C et al (2014) Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review. J Gastrointest Oncol 5:E30–E33PubMedPubMedCentral
41.
Zurück zum Zitat Prohászka Z, Varga L, Füst G (2012) The use of ‘real-time’ complement analysis to differentiate atypical haemolytic uraemic syndrome from other forms of thrombotic microangiopathies. Br J Haematol 158:424–425CrossRef Prohászka Z, Varga L, Füst G (2012) The use of ‘real-time’ complement analysis to differentiate atypical haemolytic uraemic syndrome from other forms of thrombotic microangiopathies. Br J Haematol 158:424–425CrossRef
42.
Zurück zum Zitat Tsai HM, Kuo E (2014) Eculizumab therapy leads to rapid resolution of thrombocytopenia in atypical hemolytic uremic syndrome. Adv Hematol 2014:295323CrossRef Tsai HM, Kuo E (2014) Eculizumab therapy leads to rapid resolution of thrombocytopenia in atypical hemolytic uremic syndrome. Adv Hematol 2014:295323CrossRef
43.
Zurück zum Zitat Charles Jennette JJ, Hussein Gasim AM Pathology of medical renal disease. In: Reisner HM (ed) Pathology: A Modern Case Study, 2e. McGraw-Hill Charles Jennette JJ, Hussein Gasim AM Pathology of medical renal disease. In: Reisner HM (ed) Pathology: A Modern Case Study, 2e. McGraw-Hill
45.
Zurück zum Zitat Schröder-Braunstein J, Kirschfink M (2019) Complement deficiencies and dysregulation: Pathophysiological consequences, modern analysis, and clinical management. Mol Immunol 114:299–311CrossRef Schröder-Braunstein J, Kirschfink M (2019) Complement deficiencies and dysregulation: Pathophysiological consequences, modern analysis, and clinical management. Mol Immunol 114:299–311CrossRef
46.
Zurück zum Zitat Kolb WP, Morrow PR, Tamerius JD (1989) Ba and Bb fragments of factor B activation: fragment production, biological activities, neoepitope expression and quantitation in clinical samples. Complement Inflamm 6:175–204CrossRef Kolb WP, Morrow PR, Tamerius JD (1989) Ba and Bb fragments of factor B activation: fragment production, biological activities, neoepitope expression and quantitation in clinical samples. Complement Inflamm 6:175–204CrossRef
48.
Zurück zum Zitat Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, Carreras L et al (2007) Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome [published correction appears in Proc Natl Acad Sci U S A 104:10749]. Proc Natl Acad Sci U S A 104:240–245. https://doi.org/10.1073/pnas.0603420103CrossRefPubMed Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, Carreras L et al (2007) Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome [published correction appears in Proc Natl Acad Sci U S A 104:10749]. Proc Natl Acad Sci U S A 104:240–245. https://​doi.​org/​10.​1073/​pnas.​0603420103CrossRefPubMed
50.
Zurück zum Zitat Nilsson SC, Sim RB, Lea SM, Fremeaux-Bacchi V, Blom AM (2011) Complement factor I in health and disease. Mol Immunol 48:1611–1620CrossRef Nilsson SC, Sim RB, Lea SM, Fremeaux-Bacchi V, Blom AM (2011) Complement factor I in health and disease. Mol Immunol 48:1611–1620CrossRef
56.
Zurück zum Zitat Ghiggeri GM, Bruschi M, Candiano G, Rastaldi MP et al (2002) Depletion of clusterin in renal diseases causing nephrotic syndrome. Kidney Int 62:2184–2194CrossRef Ghiggeri GM, Bruschi M, Candiano G, Rastaldi MP et al (2002) Depletion of clusterin in renal diseases causing nephrotic syndrome. Kidney Int 62:2184–2194CrossRef
57.
Zurück zum Zitat Fraga-Rodriguez GM, Brió-Sanagustin S, Turón-Viñas E, Dixon BP, Carreras-González E (2017) Eculizumab in a child with atypical haemolytic uraemic syndrome and haemophagocytic lymphohistiocytosis triggered by cytomegalovirus infection. BMJ Case Rep 2017:bcr2016219065CrossRef Fraga-Rodriguez GM, Brió-Sanagustin S, Turón-Viñas E, Dixon BP, Carreras-González E (2017) Eculizumab in a child with atypical haemolytic uraemic syndrome and haemophagocytic lymphohistiocytosis triggered by cytomegalovirus infection. BMJ Case Rep 2017:bcr2016219065CrossRef
60.
Zurück zum Zitat Noris M, Bresin E, Mele C, Remuzzi G (2007) Genetic atypical hemolytic-uremic syndrome. In: Adam MP, Ardinger HH, Pagon RA et al (eds) GeneReviews®. University of Washington, Seattle, Seattle Noris M, Bresin E, Mele C, Remuzzi G (2007) Genetic atypical hemolytic-uremic syndrome. In: Adam MP, Ardinger HH, Pagon RA et al (eds) GeneReviews®. University of Washington, Seattle, Seattle
67.
Zurück zum Zitat Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provôt F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM (2016) Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis 68:84–93CrossRef Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provôt F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM (2016) Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis 68:84–93CrossRef
72.
Zurück zum Zitat Tanaka K, Adams B, Aris AM, Fujita N et al (2021) The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab [published correction appears in Pediatr Nephrol 36:1033]. Pediatr Nephrol 36:889–898. https://doi.org/10.1007/s00467-020-04774-2CrossRefPubMed Tanaka K, Adams B, Aris AM, Fujita N et al (2021) The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab [published correction appears in Pediatr Nephrol 36:1033]. Pediatr Nephrol 36:889–898. https://​doi.​org/​10.​1007/​s00467-020-04774-2CrossRefPubMed
74.
Zurück zum Zitat Rondeau E, Scully M, Ariceta G, Barbour T et al (2020) The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment [published correction appears in Kidney Int 98:1621] [published correction appears in Kidney Int 99:1244]. Kidney Int 97:1287–1296. https://doi.org/10.1016/j.kint.2020.01.035CrossRefPubMed Rondeau E, Scully M, Ariceta G, Barbour T et al (2020) The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment [published correction appears in Kidney Int 98:1621] [published correction appears in Kidney Int 99:1244]. Kidney Int 97:1287–1296. https://​doi.​org/​10.​1016/​j.​kint.​2020.​01.​035CrossRefPubMed
77.
Zurück zum Zitat US Food and Drug Administration (2015) Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Silver Spring US Food and Drug Administration (2015) Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Silver Spring
78.
Zurück zum Zitat Ptushkin VV, Kulagin AD, Lukina EA, Davydkin IL, Konstantinova TS, Shamrai VS, Minaeva NV, Kudlay DA, Gapchenko EV, Markova OA, Borozinets AY (2020) Results of phase Ib open multicenter clinical trial of the safety, pharmacokinetics and pharmacodynamics of first biosimilar of eculizumab in untreated patients with paroxysmal nocturnal hemoglobinuria during induction of therapy. Ter Arkh 92:77–84. https://doi.org/10.26442/00403660.2020.07.000818CrossRefPubMed Ptushkin VV, Kulagin AD, Lukina EA, Davydkin IL, Konstantinova TS, Shamrai VS, Minaeva NV, Kudlay DA, Gapchenko EV, Markova OA, Borozinets AY (2020) Results of phase Ib open multicenter clinical trial of the safety, pharmacokinetics and pharmacodynamics of first biosimilar of eculizumab in untreated patients with paroxysmal nocturnal hemoglobinuria during induction of therapy. Ter Arkh 92:77–84. https://​doi.​org/​10.​26442/​00403660.​2020.​07.​000818CrossRefPubMed
79.
Zurück zum Zitat Hutterer K, Polozova A, Kuhns S et al (2019) Analytical and functional similarity of proposed Amgen biosimilar ABP 959 to eculizumab. Presented at 2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges, Long Beach, CA; May 9-10 Hutterer K, Polozova A, Kuhns S et al (2019) Analytical and functional similarity of proposed Amgen biosimilar ABP 959 to eculizumab. Presented at 2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges, Long Beach, CA; May 9-10
81.
Zurück zum Zitat Samsung Bioepis Co., Ltd (2019) A study to compare SB12 (proposed Eculizumab biosimilar) to Soliris in subjects with paroxysmal nocturnal haemoglobinuria—full text view. ClinicalTrials.gov Samsung Bioepis Co., Ltd (2019) A study to compare SB12 (proposed Eculizumab biosimilar) to Soliris in subjects with paroxysmal nocturnal haemoglobinuria—full text view. ClinicalTrials.​gov
Metadaten
Titel
Systematic review of atypical hemolytic uremic syndrome biomarkers
verfasst von
Rupesh Raina
Sidharth K. Sethi
Marie-Agnès Dragon-Durey
Amrit Khooblall
Divya Sharma
Priyanka Khandelwal
Ron Shapiro
Olivia Boyer
Hui Kim Yap
Arvind Bagga
Christoph Licht
Publikationsdatum
03.02.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Nephrology / Ausgabe 7/2022
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-022-05451-2

Neu im Fachgebiet Pädiatrie

Steigende Zahl von Skorbut-Fällen bei Kindern

Eine Erkrankung, die eigentlich der Vergangenheit angehören sollte, scheint in reichen westlichen Nationen wieder häufiger aufzutreten: Seit der Coronapandemie steigt bei Kindern und Jugendlichen in Frankreich die Inzidenz von Skorbut.

Vermeidung negativer Appendektomie und übersehener Appendizitis

Die Diagnose einer akuten Appendizitis stellt insbesondere im Kleinkindes- und Kindesalter eine Herausforderung dar. Ein israelisches Forschungsteam hat nun negative Appendektomien sowie zunächst übersehene Appendizitiden, die erst bei einem zweiten Besuch in der Notaufnahme diagnostiziert wurden, genauer untersucht.

Gespräche über Behandlungswünsche am Lebensende

Mit Jugendlichen und jungen Erwachsenen, die an einer Krebserkrankung sterben werden, finden Gespräche über ihre Wünsche für die Versorgung am Lebensende oft nur selten oder gar nicht statt. Die Autoren einer aktuellen US-amerikanische Studie mahnen, die Bedeutung solcher Gespräche nicht zu unterschätzen.

Hohe Atrophierate nach Hodentorsion im Kindesalter

Auf längere Sicht ist die Atrophierate nach einer Hodentorsion pädiatrischer Patienten erschreckend hoch. Das hat eine Studie mit jahrelanger Nachbeobachtung ergeben. Entscheidend ist die Zeit, die bis zur Detorsion verstreicht.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.